Syncom Formulations (India) Limited (SFIL) is a diversified pharmaceutical manufacturer and global distributor specializing in generic formulations. Operating from a **WHO-GMP** and **ISO 9001-2015** certified manufacturing hub in **Pithampur, Madhya Pradesh**, the company has transitioned from a domestic player into a high-growth export powerhouse. With a workforce exceeding **1,000** personnel, SFIL is currently executing a strategic pivot toward high-margin critical care, nutraceuticals, and real estate development. --- ### **Core Pharmaceutical Manufacturing & Therapeutic Portfolio** SFIL maintains a robust product basket of over **200** formulations across diverse dosage forms. The company’s manufacturing capabilities include tablets, capsules, liquid orals, vials, ampoule injections, dry syrups, ointments, and inhalers. * **ICURA Critical Care Division:** Launched in **July 2024**, this specialized sub-division focuses on intensive care and life-saving medications, representing a move into high-value medical segments. * **Schedule Formulations:** The core of the business, involving the manufacturing of regulated pharmaceutical drugs under strict **NPPA** (National Pharmaceutical Pricing Authority) guidelines. * **Consumer Healthcare & Wellness:** A growing segment focused on general wellness. SFIL emphasizes transparency, providing detailed labeling on **composition**, **side effects**, and **storage conditions**. * **Strategic Manufacturing Shift:** Effective **September 1, 2024**, the company transitioned its retail generic model from third-party arrangements to **in-house manufacturing and marketing** to capture higher integrated margins. --- ### **Financial Performance & Export Trajectory** The company has demonstrated an aggressive growth trajectory, characterized by a near-doubling of revenue and profitability in the most recent fiscal year. | Metric (Standalone) | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Total Income** | **₹480.04 Crore** | **₹271.46 Crore** | **₹239.25 Crore** | | **Net Sales** | **₹462.85 Crore** | **₹258.36 Crore** | **₹224.64 Crore** | | **Profit Before Tax (PBT)** | **₹64.66 Crore** | **₹31.76 Crore** | **₹26.57 Crore** | | **Profit After Tax (PAT)** | **₹48.87 Crore** | **₹23.62 Crore** | **₹20.07 Crore** | **Export Dominance:** SFIL has successfully penetrated more than **25 countries**. * **Export Contribution:** Rose to **83.77% (₹387.74 Cr)** in FY25, up from **69.10%** the previous year. * **Foreign Exchange Inflows:** Reached **₹374.23 Crore** in FY25, while the outgo was minimized to **₹3.38 Crore**, highlighting a strong net-positive forex position. --- ### **Infrastructure Modernization & Capacity Expansion** To support its global ambitions, SFIL recently completed a major capital expenditure program at its **Pithampur** facility, funded via a **₹40.31 Crore** equity and warrant issuance. * **Injectables Expansion:** Annual capacity increased from **2 Crore to 3 Crore units**. Commercial production for this expanded capacity commenced on **August 21, 2023**. * **Technological Upgrading:** The tablet department has been modernized with energy-efficient machinery to meet heightened regulatory scrutiny and improve production yields. * **Capital Utilization:** As of March 2023, **₹32.75 Crore** of warrant proceeds were deployed toward **Capital Work in Progress (CWIP)**. --- ### **Strategic Diversification & New Business Verticals** In **September 2025**, SFIL amended its Memorandum of Association to formalize its entry into high-growth non-pharma sectors: * **Nutraceuticals & Organic Products:** Manufacturing and trading of dietary supplements, herbal/ayurvedic preparations, and vitamins. The company launched **www.cratuscart.com**, a dedicated e-commerce platform for this line. * **Real Estate Operations:** Transitioning from passive property renting to active real estate participation. In **November 2025**, the company acquired a commercial property in **Trade Star, Andheri (E), Mumbai** for **₹51.70 Crore**. * **Wholly Owned Subsidiaries (WOS):** Three subsidiaries incorporated in July 2022—**Synmex Pharma Pvt. Ltd.**, **Sante Biotech Pvt. Ltd.**, and **Vincit Biotech International Pvt. Ltd.**—have all commenced operations to drive specialized business activities. --- ### **Sustainability & Operational Efficiency** SFIL is aggressively pursuing cost-reduction through captive renewable energy and sustainable sourcing. | Project | Capacity | Status | Impact | | :--- | :--- | :--- | :--- | | **Existing Solar Plant** | - | Operational | Produced **10.70 Lakh units**; saved **₹66.26 Lakhs** in FY25. | | **New Solar Rooftop** | **435 KWp** | Commissioned **June 12, 2025** | Estimated annual generation of **5.65 Lac units**. | * **Supply Chain Sustainability:** **30%** of inputs are sourced directly from **MSMEs** and small producers. * **Safety Standards:** Implements a **'Zero Harm'** policy with stringent contractor screening and facility management. --- ### **Capital Structure & Governance** * **Equity Base:** Following warrant conversions, the paid-up capital stands at **₹94.00 Crore** (divided into **94,00,00,000 equity shares** of **₹1/- each**). * **Dual Listing:** The company’s shares are listed on both the **BSE** and **NSE** (NSE listing effective **November 18, 2022**). * **Leadership:** **Shri Vijay Shankarlal Bankda** was re-appointed as Managing Director through **November 2026**. * **Incentives:** The company has introduced **Sweat Equity** and **ESOP** clauses to retain talent in critical **STEM** and digital roles. --- ### **Risk Management & Regulatory Landscape** SFIL operates a formal risk management framework with an independent **Internal Audit** function reporting to the Risk Management Committee. **Financial & Market Risks:** * **Currency Exposure:** Manages volatility via forward contracts. As of late 2024, outstanding forward contracts totaled **₹6,281.71 Lacs**, while un-hedged exposure stood at **₹6,073.79 Lacs**. * **Global Trade Barriers:** Potential **US tariffs** of up to **200%** on pharma imports (announced **July/August 2025**) pose a risk to export margins. * **API Dependency:** Strategic vulnerability remains due to the industry's **70-80% reliance on China** for raw materials. **Legal & Compliance Matters:** * **Taxation:** Currently contesting a **₹4.41 Crore** demand related to rejected **Input Tax Credit** under the **CGST Act**. * **Regulatory Fines:** Paid **₹4,34,240** in 2024 for a delay in constituting a Risk Management Committee as per **Regulation 21(2)**. * **Labour Codes:** Monitoring the transition to four new **Labour Codes** (effective **Nov 2025**) for potential impacts on social security and wage liabilities. * **Historical Matters:** A **₹1,00,000** SEBI penalty regarding **First Financial Services** was settled in **September 2022**, closing the proceedings.